Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial-Reference-Cited by-同舟云学术

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Published:2015-04 Issue:4 Volume:16 Page:375-384
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Weber Jeffrey S,D'Angelo Sandra P,Minor David,Hodi F Stephen,Gutzmer Ralf,Neyns Bart,Hoeller Christoph,Khushalani Nikhil I,Miller Wilson H,Lao Christopher D,Linette Gerald P,Thomas Luc,Lorigan Paul,Grossmann Kenneth F,Hassel Jessica C,Maio Michele,Sznol Mario,Ascierto Paolo A,Mohr Peter,Chmielowski Bartosz,Bryce Alan,Svane Inge M,Grob Jean-Jacques,Krackhardt Angela M,Horak Christine,Lambert Alexandre,Yang Arvin S,Larkin James

Publisher

Elsevier BV

Subject

Oncology

Reference30 articles.

1. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death;Ishida;EMBO J,1992

2. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation;Freeman;J Exp Med,2000

3. Tissue expression of PD-L1 mediates peripheral T cell tolerance;Keir;J Exp Med,2006

4. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor;Nishimura;Immunity,1999

5. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice;Nishimura;Science,2001

Cited by 2331 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in Vaccines for Melanoma;Hematology/Oncology Clinics of North America;2024-10

2. Visualized photodynamic nanomaterials activating tumor-associated immune landscape as a next-generation anticancer strategy;Coordination Chemistry Reviews;2024-10

3. Targeting PD-1/PD-L1 in tumor immunotherapy: Mechanisms and interactions with host growth regulatory pathways;Cytokine & Growth Factor Reviews;2024-10

4. Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma;Investigational New Drugs;2024-08-30

5. Prolonged in-use physicochemical and biological stability of nivolumab and pembrolizumab diluted in saline infusion bags and in partially used medication vials;Journal of Oncology Pharmacy Practice;2024-08-30